Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JWNZZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
hu4DFabv8 (V110C)-BMPEO-DM1
|
|||||
| Synonyms |
hu4DFabv8 (V110C) BMPEO DM1
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
0.9
|
|||||
| Antibody Name |
hu4DFabv8 (V110C)
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Maytansinoid DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
hu4DFabv8 (V110C)-BMPEO-DM1 linker
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Obtained from the Model Organism Data
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 83.33
|
%
|
Breast cancer model MMTV-HER2 Fo5
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.07
|
ug/mL
|
CVCL_0033
|
Breast adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.33% (Day 7) | High HER2 expression (HER2 +++) | ||
| Method Description |
An allograft was propagated from the Fo5 mmty transgenic mouse which does not respond to.or responds poorly to HERCEPTIN therapy. Subjects were treated once with ADC (25 mg/kg); and placebo PBS buffer control (Vehicle) andmonitored over 3 weeks.
|
||||
| In Vivo Model | Breast cancer model MMTV-HER2 Fo5 | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.07 ug/mL | High HER2 expression (HER2+++) | ||
| Method Description |
Exposing mammalian cells having HER2 receptors to ADC in a cell culture medium; culturing the cells for a period from about 6 hours to about 5 days; and measuring cell viability Cell-based in vitro assays were used to measure viability, cytotoxicity, and induction of apoptosis of the ADC of the invention.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.